Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman

RTTNews | hace 737
Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman

(RTTNews) - Biopharmaceutical company Protalix BioTherapeutics, Inc. (PLX) announced Tuesday that the Company's Board of Directors has appointed Eliot Richard Forster to serve on the Board of Directors as its Chairman, effective as of September 14, 2023.

In addition to Forster's appointment as Chairman and an independent director, he was also appointed to serve on the Company's Nominating Committee. Zeev Bronfeld, the current Chairman of the Company's Board of Directors, will retire on the same day.

Forster currently serves as the Non-Executive Chairman of Avacta Group PLC (AVCT), as a Non-Executive Director of Immatics NV (IMTX) and as the Non-Executive Chairman of Ochre Bio, Inc., a private biotechnology company.

Forster served as the Chief Executive Officer of F-Star Therapeutics Ltd., a clinical-stage bispecific antibodies company, until its March 2023 sale to inovoX Ltd. Prior to that, he served as CEO of Immunocure Ltd., CEO of Creabilis SA and President and CEO of Solace Pharmaceuticals Inc., each of which was a privately-held life science company.

Earlier in his career, he held positions at Pfizer Global Research & Development and Glaxo/GlaxoWellcome.

read more
Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.
RTTNews | hace 937
Australian Market Trims Early Gains In Mid-market

Australian Market Trims Early Gains In Mid-market

The Australian stock market is trimming its early gains in mid-market moves on Friday, reversing the losses in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving up near the 8,800 level, with gains in financial, energy and technology stocks partially offset by a mixed performance in mining stocks.
RTTNews | hace 42 minutos
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Friday, following the broadly positive cues from Wall Street overnight, as traders continued to digest the US Fed's interest rate cut by a quarter point and its impact on the markets. Fed officials' forecasts suggest two more rate cuts this year but just one next year, although there were significant differences of opinion about the outlook.
RTTNews | hace 1h 1min
Thai Shares May Halt Slide On Friday

Thai Shares May Halt Slide On Friday

The Thai stock market has moved lower in consecutive trading days, shedding more than 10 points of 0.8 percent along the way. The Stock Exchange of Thailand now sits just beneath the 1,300-point plateau, although it may find support on Friday.
RTTNews | hace 2h 3min
Japanese Market Notably Higher

Japanese Market Notably Higher

Extending the gains in the previous session, the Japanese market is notably higher on Friday, following the broadly positive cues from Wall Street overnight. The Nikkei 225 is moving above the 45,700 level, with gains across most sectors led by automakers, financial and technology stocks.
RTTNews | hace 2h 21min